Live Biotherapeutics Products and Microbe CDMO Market to Grow with a CAGR of 37.62% through 2030
Increasing
investment in microbiome-based therapeutic research and growing demand for
personalized probiotic treatments, is expected to drive the Global Live
Biotherapeutics Products and Microbe CDMO Market growth in the forecast period,
2026-2030
According to
TechSci Research report, “Live Biotherapeutics Products and Microbe CDMO
Market – Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030F”, the Global Live Biotherapeutics Products and Microbe
CDMO Market stood at USD 32.12
Billion in 2024 and is expected to reach USD 218.45 Billion by
2030 with a CAGR of 37.62% during the forecast period. The Global Live Biotherapeutics Products
and Microbe CDMO Market is experiencing accelerated growth driven by the
growing number of clinical-stage microbiome-based therapies across therapeutic
areas including dermatology, neurology, and immunology. Pharmaceutical firms
are moving beyond traditional probiotic applications and investing heavily in
genetically engineered live biotherapeutic strains that can deliver targeted
therapeutic payloads. Rising incidence of antibiotic-resistant infections has
intensified the search for alternative treatment modalities, further fueling
interest in live biotherapeutic products (LBPs). Government-funded microbiome
research programs and rising support for precision medicine have added momentum
to this shift. Investors are showing growing interest in early-stage biotech
firms working in the live biotherapeutics domain, reflecting increased
confidence in the market’s long-term viability.
The
contract development and manufacturing segment is being reshaped by the
increasing demand for customized microbial manufacturing, including single-use
bioreactor systems, aseptic fill-finish solutions, and lyophilization of live
organisms. CDMOs with specialized bio-manufacturing capabilities are witnessing
greater engagement from pharma firms seeking scalable and compliant solutions.
This has encouraged facility expansions and adoption of digital manufacturing
tools like electronic batch records and real-time process monitoring.
Collaborations between CDMOs and synthetic biology firms are also emerging,
enabling next-generation strain engineering and accelerated product
development. As regulatory agencies encourage early dialogue, sponsors are
actively engaging CDMOs earlier in the clinical development process to navigate
complex compliance landscapes.
The
market is not without its set of challenges. Live microbial therapeutics often
require highly controlled environments for cultivation, posing scalability
limitations. Safety profiling of novel strains and their long-term effects on
human microbiota remain areas of concern that require extensive clinical
investigation. Limited harmonization in global regulatory pathways continues to
delay product approvals and market entry. Despite these hurdles, the market
outlook remains optimistic due to the rising pipeline of investigational
therapies and the establishment of microbiome-dedicated accelerators and
incubators.
There
is significant untapped potential in pediatric, geriatric, and
immunocompromised patient groups where conventional therapies may be less
effective or poorly tolerated. Emerging research indicating microbiome
influence on vaccine response and drug metabolism could open avenues for live
biotherapeutics in personalized medicine. Strategic expansions by CDMOs into
emerging markets with local fermentation capabilities and GMP-compliant
infrastructure are poised to enhance global accessibility. Demand for over-the-counter
live microbial formulations for wellness and preventive health also presents an
opportunity for diversification beyond prescription therapeutics. These trends
position the market for sustainable expansion across therapeutic, demographic, and
geographic dimensions.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Live Biotherapeutics Products and Microbe CDMO Market”
The Global Live
Biotherapeutics Products and Microbe CDMO Market is segmented into application,
product, type of formulation, scale of operation, regional distribution, and
company.
Based on the Scale
of Operation, Clinical Scale Operations emerged as the fastest growing segment
in the Global Live Biotherapeutics Products and Microbe CDMO Market during the
forecast period. As live
biotherapeutics progress from preclinical trials to human clinical trials, the
need for clinical-scale manufacturing has surged. Clinical-scale operations
involve the production of therapeutic products in larger quantities while
maintaining the necessary control and validation to meet regulatory
requirements. This scaling up is crucial for advancing therapeutic candidates
toward commercialization. The transition to clinical scale is driven by the
increasing number of live biotherapeutic products progressing through the
clinical trial phases, particularly those focusing on microbiome-based and
genetically engineered therapies. As these products undergo clinical trials,
the demand for efficient, reliable manufacturing at clinical scale has become a
key factor in their success. CDMOs with specialized expertise in clinical-scale
production are in high demand, as they can provide critical services to support
the development of innovative live biotherapeutics. The scalability, precision,
and regulatory compliance required at this stage are driving the growth of the
clinical-scale segment, with a robust pipeline of therapeutic candidates
expected to fuel this growth throughout the forecast period.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Live Biotherapeutics Products and Microbe CDMO Market during the forecast period. This is due
to the growing investment in biotechnology, the increasing prevalence of
chronic diseases in the Asia-Pacific region. With a rapidly aging population in
several countries and an increased focus on improving healthcare outcomes, the
demand for alternative therapies like live biotherapeutics is rising. Consumers
and healthcare providers are turning to microbiome-based treatments as a viable
solution to various health issues, providing a significant market opportunity
for CDMOs specializing in this field. Moreover, Asia-Pacific's competitive
advantage lies in its ability to produce live biotherapeutic products at scale
and cost-effectively, which is further accelerated by the region’s
manufacturing capabilities and expertise. As a result, Asia-Pacific’s rapid
development in clinical-scale operations and the region's emergence as a hub for
research and manufacturing make it the fastest-growing region in the Global
Live Biotherapeutics Products and Microbe CDMO Market during the forecast
period.
Major
companies operating in Global Live Biotherapeutics Products and Microbe
CDMO Market are:
- Arrant
Bio
- 4D
Pharma
- Cerbios
- Biose
Industrie
- Assembly
Biosciences, Inc.
- Wacker
Chemie AG
- Quay
Pharmaceuticals
- NIZO
- Lonza
- Inpac
Probiotics
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Live Biotherapeutics Products
and Microbe CDMO Market is expanding due to the rising emphasis on sustainable
and eco-friendly manufacturing practices in the production of live
biotherapeutics. Companies are increasingly adopting green manufacturing
techniques, such as using renewable resources and minimizing waste, to align
with global environmental standards and reduce their carbon footprint. The
growing consumer preference for environmentally conscious products is prompting
CDMOs (Contract Development and Manufacturing Organizations) to adopt these
practices in their operations. These efforts not only contribute to
sustainability goals but also help companies meet regulatory requirements and
enhance the appeal of their products in a competitive market.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Live Biotherapeutics
Products and Microbe CDMO Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Application (C.difficle, Crohns
disease, IBS, Diabetes, Others), By Product (APIs, FDFs), By Type of
Formulation (Solid Formulations, Oral Liquids, Injectables, Others), By Scale
of Operation (Preclinical Scale Operations, Clinical Scale Operations,
Commercial Scale Operations), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global Live Biotherapeutics
Products and Microbe CDMO Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Live
Biotherapeutics Products and Microbe CDMO Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com